Experience

Revolo Biotherapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Director Discovery

  • Mar 2021 - Present



Immune Regulation Ltd

• Discovery Leader

  • Nov 2018 - Mar 2021

  Immune Regulation (formerly Peptinnovate) is a virtual clinical stage biotechnology company with focus in developing innovative immunomodulatory therapies for the treatment of chronic inflammatory conditions, particularly asthma and rheumatoid arthritis. Our two lead candidates, PIN201104 and IRL201805 are first-in-class compounds derived from endogenous immuno-regulatory proteins.Reporting directly to the CSO/COO, some of the key aspects of my current role involve: • Initiation, design and management of discovery activities within Immune Regulation through service providers or academic collaborators. • Initiate and manage collaborations with academic groups or industrial partners for progression of our clinical stage assets. • Provide respiratory, immunology and inflammation biology expertise across the organisation.• Keep abreast of relevant scientific knowledge and promoting Immune Regulation partnering efforts through attendance to relevant scientific meetings/conferences.• Scientific support to senior management, including pitching to high net worth investors and potential partners and meetings with KOLs.• Lead the translational discovery effort within the Immune Regulation team, working closely with the clinical development team in the search and development of new translational biomarkers for our current clinical assets. • Leading and management of two INNOVATE UK grants awarded to Immune Regulation in 2017 and 2018.• Support writing of patent applications and regulatory documents.



Peptinnovate Ltd

• Pharmaceutical Manufacturing

• Discovery Leader

  • Sep 2017 - Nov 2018

  Peptinnovate Ltd is a drug development company engaged in research and development of innovative peptide therapies, targeting a range of immuno–inflammatory diseases. Peptinnovate Ltd is a drug development company engaged in research and development of innovative peptide therapies, targeting a range of immuno–inflammatory diseases.



Independent

• Independent R&D Consultant

  • Jun 2017 - Aug 2017



Evotec

• Germany
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President Anti-infectives

  • May 2016 - May 2017

  • Responsible for running in vivo operations within Evotec Manchester, leading a dynamic team of 16 scientists running a range of in vivo infection models.• Main responsibilities involved:- Scientific expert contributing at a high level across in vivo pharmacology activities, including PKPD, efficacy models, study design and implementation.- Responsible for medium and short-term planning and supervision of all in vivo projects, including interaction with multiple departments as well as academic and industrial partners.- Responsible that all in vivo projects were prioritized correctly and delivered to agreed quality standards, timelines and budgets. - Deputy Project Licence Holder for existing Evotec Manchester licences.- Key business interface with clients and collaborators across the anti-infective portfolio including generating technical proposals to win new business.- Benchmarking of the group regarding current and future developments in the field and industry trends to maximize competitive advantage. - Assisting in the development and management of budgets; allocating resources and monitoring project costs. - Responsible for the performance management, career development and training of the in vivo team.• Delivered plan for expansion of in vivo activities of Evotec Manchester into new areas of opportunity beyond anti infectives focus.• Member of the Evotec In vivo Global Leadership team overviewing in vivo delivery across Evotec.• Member of Evotec Ethics and Animal Welfare Group.



Planned Career Break

• Planned Career Break

  • Jun 2015 - Apr 2016



Almirall

• Spain
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Discovery Project Team Leader

  • Jan 2014 - Jun 2015

  As well as managing the Respiratory Pharmacology section, I was approached and entrusted to lead a Drug Discovery project for one of our cough respiratory targets which was under risk to be cancelled. This was a demanding ion channel programme with important challenges in achieving the required selectivity and mode of action, which included a risk-sharing collaboration with an external partner and coordination of internal and external resources in order to progress through set timelines. Under my lead the program took off and transition from Hit-to-Lead to Lead Optimisation was achieved.

• Head Respiratory Pharmacology Section

  • Oct 2009 - Jun 2015

  1. Managed and supervised a group of 9 scientists and technicians in the running and establishment of in vitro and in vivo respiratory models. 2. Provided experience in the use of the most appropriate respiratory models (invivo and human and animal normal and disease respiratory tissues) that enable effective validation of novel drug targets, progression of lead optimisation programmes and transition of candidate compounds into clinical development. Ensured, in coordination with Programme Leaders, the best use of in vivo respiratory models along the whole drug discovery process, and contributed to the definition of the Target Compound Profile and screening cascade.3. Provided the organisation with expertise in respiratory diseases, particularly asthma and COPD, in terms of physiology, pathology mechanisms and disease models.4. Contributed to the evaluation of external product opportunities (in-licensing) and in the identification and establishment of external collaborations with excellence academic centres.6.- Transferred the relevant know how to my team and fostered the training and improvement of their methodological and scientific skills.7.- Projected the internal disease knowledge/expertise of the discovery to the external scientific community (e.g. attendance and presentation at scientific meetings, writing up peer review publications etc.). Organized internal workshops with KOLs.In was also a member of the internal Ethical Committee of Animal Experimentation, ensuring the ethical use of experimentation animals within R&D according with current regulations and watch over the animal welfare within the R&D Centre and a member of the internal Bio safety Committee, ensuring that bio safety regulations are kept across the R&D Centre.I was Almirall liaison for the international consortium severe asthma U-BIOPRED project WP6, part of the EU Innovative Medicine Initiative (IMI).



Imperial College London

• Research Services
• 700 & Above Employee

• Postdoctoral Research Associate

  • Oct 2004 - Oct 2009

  In the Respiratory Pharmacology group I was head of in vivo pharmacology and responsible for lung function and image analysis labs. My role also involved conceiving, initiating and leading research in the asthma area within our group as well as provide expertise in small animal lung function and image analysis of histopathological changes. This leadership role also included responsibilites for mentoring and training PhD students and for publicising our work at both National and International meetings. Grant writing and helping to raise funds through industrial collaborations was also a part of my role.



GSK

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Scientist

  • Jun 1999 - Oct 2004

  In GSK I successfully supported several projects based on my expertise in Nitric Oxide biology. This involved setting up and running key in vivo and in vitro models for target validation, lead op and candidate selection both in the Respiratory and Pain fields. I was also involved in several academic collaborations and supervised two PhD students. In GSK I successfully supported several projects based on my expertise in Nitric Oxide biology. This involved setting up and running key in vivo and in vitro models for target validation, lead op and candidate selection both in the Respiratory and Pain fields. I was also involved in several academic collaborations and supervised two PhD students.